In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eyenovia Inc (EYEN), with a price target of $12. The company’s shares closed yesterday at $2.88, close to its 52-week low of $2.60.
Selvaraju noted:
“Our price target is derived from a market value of the firm at $195M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -13.9% and a 21.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Eyenovia Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.
See today’s analyst top recommended stocks >>
Based on Eyenovia Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.32 million. In comparison, last year the company had a GAAP net loss of $1.16 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eyenovia, Inc. is an emerging growth clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine.
